Selected Publications

Moreno L, DuBois SG, Bird N, Knox L, Ludwinski D, Pearson ADJ, Beck-Popovic M, Bagatell R. : A 2035 Clinical Research Vision and Roadmap for High-Risk Neuroblastoma. Accepted for publication in Pediatric Blood and Cancer Page: e31660, April 2025.

Berko E, Naranjo A, Daniels AA, McNulty S, Krytska K, Druley T, Zelley K, Koneru B, Chen L, Tenney S, Polkosnik G, Irwin MS, Bagatell R, Maris JM, Reynolds CP, DuBois SG, Park JR, Mosse YP.: Frequency and clinical significance of clonal and subclonal driver mutations in high-risk neuroblastoma at diagnosis. A Children’s Oncology Group Study. Journal of Clinical Oncology ePub ahead of print March 2025.

Umaretiya P, Naranjo A, Zhang FF, Park JR, Weiss BD, Granger M, Desai AV, Ozkaynak MF, Yu AL, Aziz-Bose R, Pruitt SL, DuBois SG, Bagatell R, Bona K.: High-risk Neuroblastoma Racial and Ethnic Survival Disparities. A Children’s Oncology Group Report. JAMA Network Open 8(2): e2458531, February 2025.

Voeller J, Katzenstein HM, Naranjo A, Tenney SC, Chen L, London WB, Handler MH, Schmidt ML, Shimada H, Hogarty MD, Gastier-Foster J, Park JR, Cohn SL, Maris JM, Bagatell R, Twist CJ.: Outcomes of Patients with Intermediate-Risk Neuroblastoma Presenting with Motor Deficits Relating to Intraspinal Tumor Extension. The Children’s Oncology Group Study ANBL0531. Pediatric Blood and Cancer 72(1): e31407, January 2025.

Brown EG, Adkins ES, Mattei P, Hoffer FA, Wooton-Gorges SL, London WB, Naranjo A, Schmidt ML, Hogarty MD, Irwin MS, Cohn SL, Park JR, Maris JM, Bagatell R, Twist CJ, Nuchtern JG, Davidoff AM, Newman EA, Lal D.: Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients with Intermediate-Risk Neuroblastoma. The Children’s Oncology Group ANBL0531. J Pediatr Surgery 60(1): 161896, 2025.

Liu KX, Shaaban SG, Chen JJ, Bagatell R, Lerman BJ, Catalano PJ, DuBois SG, Shusterman S, Ioakeim-Ioannidou M, Yock TI, Shamberger R, Mattei PM, Vu L, Elhalawani H, Dusenbery KE, Vo KT, Huang MS, Friedmann AM, Diller LR, Marcus KJ, MacDonald SM, Terezakis SA, Braunstein SE, Hill-Kayser CE, Haas-Kogan DA. : Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. Radiotherapy and Oncology June 2024.

Umaretiya PJ, Naranjo A, Zhang FF, Irwin MS, DuBois SG, Bagatell R, Bona K.. 2024 May 5:e31051. doi: 10.1002/pbc.31051. Online ahead of print.PMID: 38706187 : Enrollment on upfront high-risk neuroblastoma trials by race, ethnicity, and poverty status: A report from the Children's Oncology Group. Pediatric Blood Cancer 71(7): 5:e31051, May 2024.

Bagatell R, Park J, Acharya S, Aldrin J, Allison J, Alva E, Arndt C, Bear M, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai A, DuBois, S, Fair D, Farinhas J, Harrison D, Huang F, Kreissman S, Macy M, Na B, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Hang L, Schonfeld R: NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network February 2024.

Espinoza A, Bagatell R, McHugh K, Naranjo A, Van Ryn C, Rohas-Khalil Y, Lyons KA, Guillerman RP, Kirby C, Brock P, Volchenboum SL, Simon T, States L, Miller AS, Krug B, Sarnacki S, Irtan S, Brisse H, Valteau-Coanet D, Schweinitz D, Kammer B, Granata C, Pio L, Park JR, Nuchtern J.: A Subset of Image Defined Risk Factors Predict Completeness of Resection in Children with High-risk Neuroblastoma: An International Multicenter Study. Pediatric Blood and Cancer 71(10): e31218, 2024.

Sokol E, LaBarre B, Pinto N, Kreissman S, Granger MM, Park JR, Bagatell R. Naranjo A, DuBois S.: Response to Induction Chemotherapy Modifies the Effect of Conventional Prognostic Factors in High-Risk Neuroblastoma. The Children’s Oncology Group. Eur J Cancer Ped Oncology(4), 100193, 2024.